Technical Indicators Show Bullish Momentum
The primary catalyst for the upgrade stems from a marked improvement in Venus Remedies’ technical profile. The technical trend has shifted from mildly bullish to outright bullish, reflecting stronger market momentum. Key technical indicators underpinning this change include a bullish stance on Bollinger Bands across both weekly and monthly timeframes, and a daily moving average that supports upward price movement.
Further, the KST (Know Sure Thing) oscillator is bullish on both weekly and monthly charts, reinforcing the positive momentum. While the MACD remains mildly bearish on a weekly basis, it is bullish monthly, suggesting that short-term fluctuations are overshadowed by longer-term strength. The Dow Theory also presents a mixed picture with a mildly bearish weekly signal but a bullish monthly trend, indicating that the broader market sentiment favours the stock.
On the volume front, the On-Balance Volume (OBV) indicator is mildly bearish weekly but bullish monthly, signalling accumulation over the longer term despite some short-term selling pressure. The Relative Strength Index (RSI) currently shows no significant signals, implying the stock is not overbought or oversold, which supports a sustainable upward trend.
These technical improvements have been reflected in the stock’s recent price action. Venus Remedies closed at ₹1,737.05 on 13 Aug 2026, up 4.83% from the previous close of ₹1,657.00, with intraday highs touching ₹1,739.85. The stock remains comfortably above its 52-week low of ₹423.70 and is approaching its 52-week high of ₹2,043.15, underscoring strong price resilience.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
Valuation Adjusted to Fair from Attractive
Despite the positive technical signals, the valuation grade for Venus Remedies has been downgraded from attractive to fair. This adjustment reflects the stock’s premium pricing relative to its historical and peer valuations. The company currently trades at a price-to-earnings (PE) ratio of 20.02, which is reasonable but higher than some peers in the Pharmaceuticals & Drugs industry.
Other valuation multiples include an EV to EBITDA of 13.45 and a price-to-book value of 3.50, indicating that the stock is priced at a premium but not excessively so. The PEG ratio stands at a notably low 0.13, suggesting that earnings growth is expected to outpace the valuation multiple, which is a positive sign for investors seeking growth at a fair price.
Return on capital employed (ROCE) is robust at 21.23%, while return on equity (ROE) is a healthy 15.49%, supporting the fair valuation stance. Dividend yield remains modest at 0.57%, consistent with the company’s reinvestment focus for growth rather than income distribution.
When compared to peers such as Ind-Swift Laboratories and Fredun Pharma, which are rated as very expensive with PE ratios above 35, Venus Remedies’ valuation appears more reasonable. This relative valuation supports the upgrade to a Buy rating despite the shift from attractive to fair.
Strong Financial Trends Underpin Confidence
Venus Remedies has demonstrated exceptional financial performance in recent quarters, which has been a key factor in the rating upgrade. The company reported a net profit growth of 139.27% in Q1 FY26-27, with profit before tax (PBT) excluding other income rising by 198.37% to ₹27.42 crores. This marks the seventh consecutive quarter of positive results, highlighting consistent operational strength.
Operating profit has grown at an impressive annual rate of 56.81%, reflecting efficient cost management and expanding margins. The company is net-debt free, which enhances its financial stability and capacity to invest in growth initiatives without leverage concerns.
Return on capital employed (ROCE) for the half-year period reached a peak of 19.85%, signalling effective utilisation of capital resources. Over the past year, Venus Remedies’ stock has delivered a remarkable 260.65% return, vastly outperforming the Sensex, which declined by 3.05% over the same period. Over longer horizons, the stock’s returns remain stellar, with a 10-year return of 1,930.45% compared to Sensex’s 177.35%.
These financial trends underscore the company’s strong fundamentals and growth potential, justifying the upgrade to a Buy rating despite the micro-cap classification.
Quality Assessment Remains Positive
The company’s quality grade remains strong, supported by its consistent earnings growth, net-debt free status, and robust return metrics. Venus Remedies’ Mojo Score stands at 74.0, with the Mojo Grade upgraded from Hold to Buy on 13 Aug 2026. This score reflects a balanced assessment of the company’s fundamentals, technicals, and valuation.
While the company is classified as a micro-cap, its operational performance and market returns rival those of larger peers. The stock’s consistent outperformance of the BSE500 index over the last three years further attests to its quality and resilience in a competitive sector.
However, one risk factor to consider is the absence of domestic mutual fund holdings, which currently stand at 0%. This lack of institutional ownership may indicate some hesitation among large investors, possibly due to the company’s size or valuation levels. Investors should monitor this aspect as it may impact liquidity and price stability in the future.
Want to dive deeper on Venus Remedies Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Outlook and Investment Considerations
Venus Remedies Ltd’s upgrade to a Buy rating is well supported by a confluence of factors. The technical indicators suggest sustained bullish momentum, while the company’s financial results demonstrate strong growth and profitability. Although the valuation has shifted from attractive to fair, it remains reasonable relative to peers, especially given the company’s growth prospects and low PEG ratio of 0.13.
Investors should note the company’s micro-cap status and limited institutional ownership, which may introduce volatility. Nonetheless, the stock’s impressive returns over multiple timeframes, including a 551.56% gain over three years and a staggering 1,930.45% over ten years, highlight its potential as a long-term growth investment within the Pharmaceuticals & Biotechnology sector.
In summary, Venus Remedies offers a compelling combination of quality, improving technicals, solid financial trends, and fair valuation, making it a favourable pick for investors seeking exposure to a high-growth pharmaceutical company with a proven track record.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
